Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Burfiralimab, an antibody targeting VIM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tobevibart, an antibody targeting Human Papillomavirus Envelope Protein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tuparstobart, an antibody targeting LAG3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Varokibart, an antibody targeting IL5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sotiburafusp, an antibody targeting VEGFR-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tegoprubart, an antibody targeting CD40LG.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Temtokibart, an antibody targeting IL22RA1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Resugosbart, an antibody targeting Sclerostin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Renvistobart, an antibody targeting TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sabestomig, an antibody targeting PD-1 × HAVCR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Porustobart, an antibody targeting CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nelistotug, an antibody targeting TACTILE.